OSMAC Strategy: A promising way to explore microbial cyclic peptides.

Anticancer Antimicrobial Cyclic peptides Microorganisms OSMAC strategy Secondary metabolites

Journal

European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510

Informations de publication

Date de publication:
15 Mar 2024
Historique:
received: 18 09 2023
revised: 12 01 2024
accepted: 22 01 2024
medline: 18 3 2024
pubmed: 21 2 2024
entrez: 20 2 2024
Statut: ppublish

Résumé

Microbial secondary metabolites are pivotal for the development of novel drugs. However, conventional culture techniques, have left a vast array of unexpressed biosynthetic gene clusters (BGCs) in microorganisms, hindering the discovery of metabolites with distinct structural features and diverse biological functions. To address this limitation, several innovative strategies have been emerged. The "One Strain Many Compounds" (OSMAC) strategy, which involves altering microbial culture conditions, has proven to be particularly effective in mining numerous novel secondary metabolites for the past few years. Among these, microbial cyclic peptides stand out. These peptides often comprise rare amino acids, unique chemical structures, and remarkable biological function. With the advancement of the OSMAC strategy, a plethora of new cyclic peptides have been identified from diverse microbial genera. This work reviews the progress in mining novel compounds using the OSMAC strategy and the applications of this strategy in discovering 284 microbial cyclic peptides from 63 endophytic strains, aiming to offer insights for the further explorations into novel active cyclic peptides.

Identifiants

pubmed: 38377824
pii: S0223-5234(24)00055-2
doi: 10.1016/j.ejmech.2024.116175
pii:
doi:

Substances chimiques

Peptides, Cyclic 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

116175

Informations de copyright

Copyright © 2024 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Yu Zhang (Y)

State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Li Feng (L)

State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Xinya Hemu (X)

State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Ning-Hua Tan (NH)

State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: nhtan@cpu.edu.cn.

Zhe Wang (Z)

State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 211198, China. Electronic address: wangzhe@cpu.edu.cn.

Articles similaires

Aspergillus Hydrogen-Ion Concentration Coculture Techniques Secondary Metabolism Streptomyces rimosus
Drought Resistance Gene Expression Profiling Gene Expression Regulation, Plant Gossypium Multigene Family
Citrus Phenylalanine Ammonia-Lyase Stress, Physiological Multigene Family Phylogeny
Arabidopsis Amorphophallus Plants, Genetically Modified Phylogeny Droughts

Classifications MeSH